Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function
Sernova Corp. presented positive interim data from its Phase I/II clinical trial, showing sustained insulin independence in T1D patients with the Cell Pouch Transplant System. Histological data confirmed well-vascularized, functioning islets secreting insulin, glucagon, and somatostatin for over 5 years, with no detrimental fibrotic tissue. The Cell Pouch also demonstrated retrievability and safety.
Related Clinical Trials
Highlighted Terms
Related News
Sernova Corp. presented positive interim data from its Phase I/II trials for its Cell Pouch™ Transplant System in treating Type 1 diabetes, showing long-term survival and function of islet cells. The system aims to provide a 'functional cure' by delivering therapeutic cells as a pseudo-organ. The data, presented by Dr. Piotr Witkowski, indicated robust vascularization and no detrimental tissue in the pouch after over five years. Sernova's CEO, Jonathan Rigby, highlighted the potential impact on quality of life for Type 1 diabetics. The company's technology also targets other chronic diseases and has potential for broader cell and protein delivery.
Sernova Corp. presented positive interim data from its Phase I/II clinical trial, showing sustained insulin independence in T1D patients with the Cell Pouch Transplant System. Histological data confirmed well-vascularized, functioning islets secreting insulin, glucagon, and somatostatin for over 5 years, with no detrimental fibrotic tissue. The Cell Pouch also demonstrated retrievability and safety.